Dupixent (dupilumab)

pCPA File Number: 23221
Negotiation Status:
Active Negotiation
Indication(s):
Prurigo nodularis
Sponsor/Manufacturer:
Sanofi-Aventis Canada Inc.
CDA-AMC Project Number:
SR0876-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable